Heart Failure

Investigators found that treating for CSA in the patient population significantly decreases mortality risk—despite previous clinical warnings.

The supplemental BLA seeks FDA approval for alirocumab (Praulent) as a treatment to reduce overall risk of major adverse cardiovascular events.

Interestingly, increased distress led to a higher risk of stroke for women, while distressed men had a higher risk of heart attack.

The risk of acute coronary syndrome recurring after hospitalization was not found to be increased in individuals infected with HIV.

Though previous research showed telemonitoring and pharmacist consultation helped patients manage blood pressure for about one year, researchers have been unsure whether it would provide sustained, long-term benefits in at-risk patients.

Patients administered the FDA-approved therapy reported tripled rates of weight-loss, along with noninferiority for risk of major cardiovascular events, over 1 year and an extension period.

The update reported significant improvements in future cardiovascular risks in patients at risk for chronic angina initially referred for CTA plus standard care, versus those only referred to standard care.

In an analysis of 118 clinical trials since 2001, investigators found females and minorities comprised just 27% and 22% of the total patient population, respectively.

For patients with acute coronary syndrome and depression, taking escitalopram to treat depression resulted in significantly fewer major cardiac events compared to patients given placebo.

Women and men are more likely to survive when treated by female doctors compared to male doctors, but the difference in heart attack survival is greater for women.

Researchers were able to rule out myocardial infarction in 30% of patients immediately, and another 25% of patients at 1 hour. By 3 hours, the assay had successfully ruled out MI in 83.8% of patients, versus the 80.4% ruled out under the conventional assay.

The PocketECG Cardiac Rehabilitation System provides electrocardiography (ECG) monitoring and alerts during cardiac rehabilitation.

A review of literature on depression and anxiety in patients with heart failure reports that 21.5% have depressive symptoms and 19% meet the criteria for a depressive disorder—2 to 3 times higher than rates in the general population.

The paradigm of obesity is complex and requires a multi-disciplinary approach, but it is one of the most gratifying experiences for both the physicians and patient when they see the results of weight loss.

Results showed that participants with doctor-diagnosed asthma had a 38% increased risk of developing AF compared to those without asthma.

A few months after performing a first-of-its-kind procedure in the US, members of the John Ochsner Heart and Vascular Institute surgical team explore what led to the surgical success.

The Cleveland Clinic’s pioneer of minority programs plans to end health disparity.

AF is associated with major disease burden, predominately in the form of cardiovascular comorbidities. As a direct oral anti-coagulant, rivaroxaban has been a proven inhibitor of ischemic stroke risks in patients with AF.

Trials of valbenazine for TD do not find that the treatment adds to cardiovascular disease risks associated with schizophrenia or the cardiovascular complications of antipsychotics.

In a comparison of canagliflozin to other SGLT-2 inhibitors and anti-hyperglycemic therapies, the drug was found to decrease hospitalization from heart failure risk, and carry no extra risk for leg or foot amputation.

Cardiovascular disease is the leading cause of death in women. And yet, the crux of concern for disease risk is designated to male patients.

During the first 12 weeks of study, the investigated therapy had also reduced patient hypoglycemia event rates by 23% and low blood sugar event rates by 26% versus comparative therapy.

Empagliflozin has reported positive outcomes in renal conditions and heart failure in T2D patients. Now what?

Post-hoc analyses from the EMPA-REG OUTCOME study found consistent benefits for the therapy in comorbidities versus placebo.

Xultophy was originally indicated as a therapy to improve glycemic control in adults with T2D mellitus that is inadequately controlled by basal insulin or liraglutide.